Clearbridge Investments LLC Has $47.88 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Clearbridge Investments LLC trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,031 shares of the biopharmaceutical company’s stock after selling 2,695 shares during the quarter. Clearbridge Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $47,880,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Sound Shore Management Inc CT acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $64,677,000. Ellerson Group Inc. ADV boosted its holdings in Regeneron Pharmaceuticals by 49.2% during the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock valued at $4,556,000 after purchasing an additional 2,671 shares in the last quarter. Nordea Investment Management AB boosted its holdings in Regeneron Pharmaceuticals by 118.1% during the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares in the last quarter. Oppenheimer & Co. Inc. boosted its holdings in Regeneron Pharmaceuticals by 7.2% during the third quarter. Oppenheimer & Co. Inc. now owns 23,714 shares of the biopharmaceutical company’s stock valued at $13,334,000 after purchasing an additional 1,597 shares in the last quarter. Finally, TD Asset Management Inc boosted its holdings in Regeneron Pharmaceuticals by 15.9% during the third quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock valued at $210,437,000 after purchasing an additional 51,407 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $616.18 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The company has a 50 day moving average price of $701.59 and a 200 day moving average price of $741.02. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $503.25 and a fifty-two week high of $821.11. The stock has a market capitalization of $65.14 billion, a PE ratio of 15.01, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same quarter in the previous year, the company posted $8.22 EPS. Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares in the company, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on REGN shares. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Finally, JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $792.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.